
Clinical trials are becoming more complex, more distributed, and more data-heavy. For contract research organizations (CROs), that means greater operational strain across every aspect of study execution. The demand for speed, precision, and transparency is rising, while margins and timelines continue to shrink. To stay competitive, CROs need to do more than keep up, they…

Why Rare Disease and Specialty Pharma Trials Need Custom Workflows Rare disease and specialty pharma trials operate under very different conditions than large, conventional studies. Instead of enrolling hundreds or thousands of patients at a limited number of clinical sites, these studies often include only a small number of participants spread across wide geographic areas.…

Adaptive clinical trials are built to respond to evidence as it emerges, allowing researchers to make changes midstream without compromising study integrity. Adjustments to dosing, enrollment, or treatment arms can be made based on interim analyses, creating opportunities for faster timelines, better resource allocation, and improved patient safety. This promise depends on one critical factor:…

Clinical development rarely moves in a straight line. Programs expand across countries, add cohorts, refine eligibility criteria, and shift timelines in response to emerging data. For pharmaceutical sponsors, the common thread is scale. The ability to move from a handful of sites to hundreds, from one language to many, and from a single study to…

Electronic data capture, or EDC, continues to be a constant in modern clinical research studies. For pharmaceutical sponsors running complex, multi-phase programs, EDC can help connect protocol design, site operations, data review, and submission preparation. Done well, it gives every stakeholder a single, reliable source of truth. It speeds startup, reduces risk, and builds a…

In the modern clinical research environment, improving patient outcomes is both a regulatory imperative and an ethical priority. The tools used to collect, manage, and analyze study data can meaningfully influence the speed, quality, and effectiveness of therapeutic development. Among these tools, eSource software is increasingly recognized for its ability to streamline workflows, reduce errors,…

Serious adverse events (SAEs) are among the most critical data points collected during a clinical trial. The timeliness and accuracy of SAE reporting can mean the difference between a manageable issue and a significant safety crisis. As regulatory expectations increase and trial designs grow more complex, sponsors and CROs need tools that accelerate safety workflows…

The Post-Market Shift: From Sites to Data Streams Phase IV trials used to mean tracking long-term outcomes by continuing to work with the same clinical sites involved in earlier phases. But that model is fading fast. Today, real-world data (RWD) from patients, providers, and everyday devices is transforming how post-approval research is designed and conducted.…

Clinical trials in pain and neurological research have historically faced steep hurdles: lengthy timelines, high costs, and subjective data endpoints that often obscure true efficacy. With only around 15% of central nervous system (CNS) drugs successfully moving from Phase 1 to approval, researchers clearly need more reliable tools. Artificial intelligence (AI) analytics has emerged as…

Regulatory Risks of Wearables in Clinical Trials Are Real (and Avoidable) Wearables have become indispensable in modern clinical trials, tracking vital signs, capturing real-world evidence, and improving patient engagement from anywhere. But as their use increases, so do the regulatory risks. While wearable devices open the door to faster, more patient-centric research, they also introduce…